Skip to main content


Continuing Education (CME)
2nd Annual Conference on CNS Clinical Trials and Brain Metastases
August 12-13, 2022 in Toronto, ON, CAN

This activity is jointly provided by Global Education Group and the Society for Neuro-Oncology, and in collaboration with ASCO. 

This activity is supported by an educational grant from Medtronic, Inc.

Target Audience

Neuro-oncologists (both neurology and medical oncology-trained), Medical Oncologists, Neurosurgeons, Neuro-radiologists, Neuropathologists, Neuropsychologists, Radiation Oncologists, Basic and Translational Scientists, Basic and Clinical Science Trainees, Allied Health Professionals, Palliative Care Professionals, Industry Professionals, Regulatory and Government Officials, Patient Advocates, and Nursing Professionals.

Statement of Need/Program Overview
The Second Annual Conference on CNS Clinical Trials and Brain Metastases, Co-Sponsored by SNO and ASCO — an interactive, interdisciplinary conference on primary and metastatic CNS malignancies — is being held August 12-13, 2022, in Toronto. The goal of this annual Conference is to provide a deeper dive into the area of neuro-oncology clinical trials, to understand how we can make more significant improvements in survival and quality of life of patients with primary and metastatic cancers of the central nervous system. 

This collaborative conference will address the needs of patients with glioblastoma and intracranial malignancy in general, both primary and secondary, and stimulate clinical research in these areas of great unmet clinical need. Research advocating new approaches, out of the box ideas and reforms in the area of neuro-oncology clinical trials will be presented and discussed. The structure will provide a forum that cuts across a large breadth of disciplines and emphasizes aspects of clinical trial design, statistics and interpretation of trial outcomes to develop a better understanding of why numerous glioblastoma and other neuro-oncology clinical trials do not achieve their ultimate objective of prolonging survival of patients and other meaningful clinical measures. In addition, it will provide a forum that promotes collaboration and cross-fertilization of novel ideas between those invested in the care of patients with primary and secondary malignancies of the CNS. 

Educational Objectives
After completing this activity, the participant should be better able to:
  • Describe how the metastatic brain tumor microenvironment can be leveraged to optimize tumor management.
  • Describe multidisciplinary care options for the management of primary and secondary brain tumors.
  • Discuss new developments in therapeutic approaches in the treatment of primary and secondary brain tumors.
  • Describe recent experimental and clinical advances in the treatment of systemic brain metastases.
  • Discuss new therapeutic approaches for malignant diseases of the spinal cord and leptomeninges.
  • Identify strategies to integrate supportive and palliative care into the care of patients with primary and metastatic cancers of the CNS.
  • Describe basic science’s (translational and correlative) role for discovery of new effective therapies for the management of primary and metastatic brain tumors.
  • Discuss current and future approaches for integrating neuroimaging into CNS cancer clinical trials.
  • Identify challenges in pediatric investigations that result in the development of clinical trials.
  • Identify challenges for the development and approval of novel therapies for CNS cancers.

Click here to view all faculty speakers and moderators.

CME Program Agenda
Click here to view current program*.  

*Please note: All educational presentations on August 12 - 13, 2022, are a CME activity. All presentations on August 11th are a non-CME activity. Additionally, all posters are non-CME.

Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Society for Neuro-Oncology. Global is accredited by the ACCME to provide continuing medical education for physicians.

* This CME/CE activity complies with all requirements of the federal Physician Payment Sunshine Act. If a reportable event is associated with this activity, the accredited provider managing the program will provide the appropriate physician data to the Open Payments database.

Physician Credit Designation
Global Education Group designates this live activity for a maximum of 13.25 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit
In order to receive credit for this activity, the participant must attend the meeting in-person and complete the program evaluation. An individualized CME/CE evaluation link will be emailed to each participant within one week of the conference conclusion from "[email protected]" with the subject line "CME/CE WebSurvey link." 

Deadline to claim CE Credit will be Friday, September 30, 2022 at 11:59pm ET.

Refund/Cancellation Policy
The deadline for cancellations with refund is Monday, August 1, 2022. Cancellations must be received in writing and a $50 cancellation fee will be assessed. Cancellations received after the deadline date cannot be refunded, but the meeting registration can be transferred to another person with written authorization

Please note that your SNO or ASCO membership must be current if you have chosen to register as a SNO or ASCO member. SNO reserves the right to confirm that you have registered in the correct category.

Payment must be received in full before access to the meeting can be granted.

Email all cancellation and transfer requests to Program Registrar Caroline Noor, [email protected].

Disclosure of Conflicts of Interest
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global.  All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias. 

All relevant financial relationships have been mitigated.

Click here for the Disclosure list of all individuals in control of content for the program.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Society for Neuro-Oncology do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or [email protected] .


Click here to return to the 2nd Annual Conference on CNS Clinical Trials and Brain Metastases Conference homepage.